About evelo biosciences inc - EVLO
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.
EVLO At a Glance
Evelo Biosciences, Inc.
One Kendal Square, 600/700
Cambridge, Massachusetts 02139
| Phone | 1-617-577-0300 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -114,527,000.00 | |
| Sector | Health Technology | Employees | 66 | |
| Fiscal Year-end | 12 / 2023 | |||
| View SEC Filings |
EVLO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.387 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.356 |
EVLO Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,735,257.576 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
EVLO Liquidity
| Current Ratio | 4.161 |
| Quick Ratio | 4.161 |
| Cash Ratio | 3.868 |
EVLO Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -150.385 |
| Return on Equity | -6,232.762 |
| Return on Total Capital | -248.184 |
| Return on Invested Capital | -214.277 |
EVLO Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 110.818 |
| Total Debt to Total Assets | 79.356 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 105.923 |